8-K ·Filed Apr 22, 2026
8-K Item 2.02: Earnings release
Actionable Insight • Neutral
Monitor the company's earnings call on May 5, 2026 for Q1 2026 financial results and updated guidance. No material information was released in this announcement.
Final — all horizons settled through T+60d ⚠ clustered
SUPN ▼ -5.89% at T+60d
NEUTRAL call ✗ call lost -5.89% · α vs SPY -10.91% · entry $50.39 → $47.42
T+1d
-1.25%
call -1.25% · α -2.04%
$49.76
settled 5mo ago
T+5d
-3.65%
call -3.65% · α -5.13%
$48.55
settled 5mo ago
T+20d
-3.37%
call -3.37% · α -8.01%
$48.69
settled 5mo ago
T+60d
-5.89%
call -5.89% · α -10.91%
$47.42
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Supernus Pharmaceuticals announced it will report its Q1 2026 financial results on May 5, 2026, after market close. This filing is a standard earnings announcement notice with no financial results disclosed.
Key Financial Metrics
Guidance
$840M-$870M
maintained
Key Facts
- Supernus Pharmaceuticals will report Q1 2026 financial results on May 5, 2026 after market close.
- Management will host a conference call on May 5, 2026 at 4:30 p.m. ET to discuss results.
- No financial data was released in this 8-K filing.
Financial Impact
No financial impact from this filing — results not yet disclosed.
Risk Factors
- Earnings miss or lowered guidance in upcoming report could pressure stock.
- Supply chain or commercial execution risks for key products like ONAPGO and ZURZUVAE remain.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001356576-26-000015 |
| Exhibit: ex-99104x22xearningscallan.htm | 0001356576-26-000015 |
| Document: 0001356576-26-000015-index-headers.html | 0001356576-26-000015 |
| Document: 0001356576-26-000015-index.html | 0001356576-26-000015 |
| Document: 0001356576-26-000015.txt | 0001356576-26-000015 |
| 8-K Data (Synthetic) | 0001356576-26-000015 |
20 reports for SUPN
75% Hit rate best @ T+1▲ +8.46%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | DEFM14A | $41.49 $42.78 | ▲ +3.11% | ▲ +3.00% | $42.38 (+2.15%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.38 (−2.01%) |
Aug 3, 2026 8w ago | 8-K | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.38 (−2.01%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.38 (−7.87%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.38 (−7.87%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.38 (−7.87%) |
Aug 3, 2026 8w ago | DEFA14A / 425 / 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.38 (−7.87%) |
Jul 22, 2026 10w ago | 8-K | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.38 (−10.19%) |
Jul 22, 2026 10w ago | Press Release | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.38 (−10.19%) |
Jul 20, 2026 10w ago | Court Ruling | $47.42 $46.20 | ▼ −2.57% | ▼ −2.15% | $42.38 (−10.63%) |
Showing 10 of 20
US Market Status
Market Closed — Opens Mon (65h 25m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access